Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Quest Pharmatech Inc QPTFF


Primary Symbol: V.QPT

Quest PharmaTech Inc. is a Canadian biopharmaceutical company. The Company is developing products to improve the quality of life. It is developing the proprietary, MAb-AR9.6, targeting MUC16 as a diagnostic agent for cancer. MAb-AR9.6 is licensed from the University of Nebraska Medical Centre and is in late preclinical stage development. The Company has a 42.5% ownership interest in OncoQuest Inc., which is a biotechnology company developing combinatorial immunotherapy products for the treatment of cancer. OncoQuest Inc.’s technology platform includes a panel of tumor antigen specific monoclonal antibodies of the immunoglobulin G (IgG) and E (IgE) class targeting CA125, MUC1, PSA, Her2/neu, CA 19.9 and TAG72; and the application of combinatorial immunotherapy to enhance tumor specific immunity and clinical outcome. The Company also has a 23% ownership interest in OncoVent, which is developing antibody-based immunotherapeutic products for cancer in the Greater China territory.


TSXV:QPT - Post by User

Post by ARIMA11on Jan 24, 2024 8:13pm
219 Views
Post# 35844157

Interesting

Interestinghttps://www.annalsofoncology.org/article/S0923-7534(19)32244-6/fulltext

Conclusions
Careful consideration should be given to the decision to terminate a study for futility, as futility calculations do not always get it right and can represent an inadequate estimate of the final trial results. Given the consequences of early termination, it may be reasonable to evaluate how the termination criteria behaved over time. Decisions to terminate a study should always be made after due consideration of all aspects of the study, including toxicity and other endpoints.
<< Previous
Bullboard Posts
Next >>